Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
08/2010
08/04/2010CN101795690A Method for reducing intracranial pressure
08/04/2010CN101795675A Colonic delivery using Zn/pectin beads with a Eudragit coating
08/04/2010CN101795670A Liquid formulation of G-CSF
08/04/2010CN101792752A Metarginase and recombination expression method and use thereof
08/04/2010CN101792489A Preparation and application of human galectin-9 deletant for enhancement of immune response
08/04/2010CN101792485A Alpha-type conus polypeptide and application thereof
08/04/2010CN101792483A Novel peptides as NS3-serine protease inhibitors of hepatitis c virus
08/04/2010CN101791409A peptide vectors
08/04/2010CN101791397A Application of RNase III protein in staphylococcus aureus for preventing and treating staphylococcus aureus infection
08/04/2010CN101791396A Controlled release compositions for interferon based on PEGT/PBT block copolymers
08/04/2010CN101791395A Application of phospholipid scramblase 1 in preparing anti-hepatitis B virus infective medicament
08/04/2010CN101791394A Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
08/04/2010CN101284869B Antiviral polypeptides and use
08/04/2010CN101128548B Antimicrobial cementitious composition
08/04/2010CN101020045B New use of agglutinin
08/03/2010US7767881 Mixture of histamine receptor protein and histamine receptor antagonist
08/03/2010US7767800 Comprises lymphadenopathy viral sequences for diagnosis of aquired immuno-depressive syndromes
08/03/2010US7767790 Apotosis inducing viral protein, in combination with defective p53 protein, for use in treatment of cell proliferative and autoimmune disorders
08/03/2010US7767788 Folding protein functioning as a molecular switch
08/03/2010US7767787 Substance for obtaining highly effective tumor medications as well as a process
08/03/2010US7767786 Neural regeneration peptides and methods for their use in treatment of neural injury or degeneration
08/03/2010US7767654 treating bleeding disorder selected from a chronic or acute bleeding disorder, a congenital coagulation disorder caused by a blood factor deficiency, and an acquired coagulation disorder, by administering a composition comprising a procoagulant amount of a fucoidan
08/03/2010US7767649 Gamma aminobutyric acid antagonist; naphthylalanine; antiepileptic agents; antidepressants; anxiolytic agents; psychological disorders; neurodegenerative disorders; analgesics; drug withdrawal
08/03/2010US7767648 Prostate specific antigen; immobilization; antiproliferative agents; drug delivery; contain cleavage sites specifically cleaved by prostate specific membrane antigen (PSMA); useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs
08/03/2010US7767647 proteolytic activation of recombinantly-produced Factor IX; dissolving a paste of Cohn fraction IV-1, adsorbing onto calcium phosphate, eluting and applying to an anion exchange resin, eluting prekallikrein impurities and then factor IXa
08/03/2010US7767645 2-{(9S,10S,14R,18S)-7,16,19-Triaza-18-(carbamoylmethyl)-14-[(5-methyl indolyl)methyl]-8,17,20-trioxo-10-[4-(phosphonomethyl)phenyl]spiro[5.14]icos-11-en-9-yl}acetic acid; anticarcinogen
08/03/2010US7767644 contains at least four amino acids selected from leucine, isoleucine, threonine, glutamic acid, aspartic acid and phenylalanine, and in which the addition of preservatives, urea or human serum albumine can be foregone; storage stability
08/03/2010US7767643 A reduced carbohydrate or oxidized carbohydrates links to erythropoietin; cognitive activator for treating nervous system disorder, anticardiovascular agents, treating vision defects, respiratory diseases, kidney and urinary diseases
08/03/2010US7767642 Interaction between MUC1 and beta -catenin can be interrupted using polypeptides or antibodies that specifically bind to the binding site on MUC1, whereby interruption provides the beneficial effect of inhibiting, reducing, and/or retarding invasiveness and metastasis
08/03/2010US7767641 promoting endothelial cell adhesion, spreading and migration in treating a condition or disease characterized by pathological vascular remodeling in a subject in need thereof by administering a composition comprising Nogo-B or a fragment of Nogo-B comprising 1- 200 of the N-terminus
08/03/2010US7767429 use to treat glycosaminoglycan associated pathologies such as eye disorders or tumors; sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes; transgenic animals; dosage forms; HYLENEX RECOMBINANT tradename
08/03/2010US7767418 Expression vector comprising nucleotide sequences coding immunoglobulin fusion comprising transient receptor potential cation channel for use in identifying modulator for treatment and prevention of nervous system disorders
08/03/2010US7767417 Prenyl-electrostatic switch, and methods of use
08/03/2010US7767402 Methods and compositions for controlling appetite and modulating insulin sensitivity
08/03/2010US7767232 Control of nitric oxide bioactivity by perfluorocarbons
08/03/2010US7767224 Method for the continuous production and coating of self-adhesive compounds on the basis of SBC that includes at least one pharmaceutically active substance
08/03/2010US7767223 Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use
08/03/2010US7767219 Drug core encapsulated with multilayer polyelectrolyte shells
08/03/2010US7767211 S.aureus polypeptides
08/03/2010US7767204 Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
08/03/2010US7767201 Vascular cells genetically altered to over-express angiogenic proliferation and maturation factors; treatment of atherosclerosis using same
08/03/2010US7767199 Expression vector comprising interleukin-21sequences for use in improved transcription of exogenous nucleotide sequences
08/03/2010US7767198 Aerosolizing dry powder of interleukin-4 receptor with carbohydrage, lipid, buffer, peptide, protein, Group II metal, or oligopeptide excipient; small aerodynamic particle size; dispersion into gas stream to make inhalant; high dispersibilities
08/03/2010CA2512926C Methods and compositions for inhibition of angiogenesis
08/03/2010CA2492724C The use of epidermal growth factor as a gastrointestinal therapeutic agent
08/03/2010CA2490191C Modified 2' and 3' -nucleoside prodrugs for treating flaviviridae infections
08/03/2010CA2468295C Glycoprotein remodeling using endoglycanases
08/03/2010CA2412183C Rtvp based compositions and methods for the treatment of prostate cancer
08/03/2010CA2386325C Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes, dna viruses and retroviruses
08/03/2010CA2373130C Method of stimulating growth in aquatic animals using growth hormones
08/03/2010CA2361949C Heparin, or heparin conjugate, islets of langerhans
08/03/2010CA2312475C Method of suppressing .beta.-amyloid-related changes in alzheimer's disease
08/03/2010CA2294101C A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor
08/03/2010CA2265853C Inhibition of apoptosis using interleukin-1.beta.-converting enzyme (ice)/ced-3 family inhibitors
08/03/2010CA2263106C Humanized immunoglobulin reactive with .alpha.4.beta.7 integrin
08/03/2010CA2262423C Human monoclonal antibodies specific for hepatitis c virus (hcv) e2 antigen
08/03/2010CA2247247C Troponin subunits and fragments useful as angiogenesis inhibitors
08/03/2010CA2224777C New immunoregulatory protein lst-1
08/03/2010CA2217462C Controlled release biodegradable micro- and nanospheres containing cyclosporin
08/03/2010CA2190365C Pigment epithelium-derived factor: characterization, genomic organization and sequence of the pedf gene
08/03/2010CA2188813C Angiostatin protein, nucleic acids encoding the same and methods of detection
08/03/2010CA2178057C Epstein-barr virus peptides and antibodies against these peptides
08/03/2010CA2164848C Interleukin-2 stimulated t lymphocyte cell death for the treatment of autoimmune diseases, allergic disorders, and graft rejection
08/03/2010CA2133873C Tnf inhibitors
07/2010
07/29/2010WO2010085790A1 A single chain antibody for the detection of noroviruses
07/29/2010WO2010085682A2 Stabilized fc polypeptides with reduced effector function and methods of use
07/29/2010WO2010085661A1 Modified peptides and their use
07/29/2010WO2010085643A1 Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders
07/29/2010WO2010085588A2 Modulating angiogenesis
07/29/2010WO2010085539A1 Methods and compositions based on shiga toxin type 2 protein
07/29/2010WO2010085370A2 Systems and methods to facilitate online transactions
07/29/2010WO2010085262A1 In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
07/29/2010WO2010085145A1 Method for the prophylaxis or treatment of flushing
07/29/2010WO2010085086A2 Modified human thrombopoietin polypeptide fragment and manufacturing method thereof
07/29/2010WO2010084851A1 Peptide capable of binding to immunoglobulin
07/29/2010WO2010084488A1 Mir-21 promoter driven targeted cancer therapy
07/29/2010WO2010084173A1 Stable growth hormone compounds
07/29/2010WO2010084169A2 Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
07/29/2010WO2010083842A2 Expression of neuropeptides in mammalian cells
07/29/2010WO2010083611A1 Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex
07/29/2010WO2010083589A1 Biofilm-removing antimicrobial compositions and uses thereof
07/29/2010WO2010083573A1 The treatment or prophylaxis of organ and tissue fibrosis via modulation of cell division autoantigen (cda1)
07/29/2010WO2010063839A3 Targets for treatment of chlamydial infections
07/29/2010WO2010048340A3 Novel semi-synthetic glycopeptides as antibacterial agents
07/29/2010WO2010041140A3 Treatment of proliferative disorders with a death receptor agonist
07/29/2010WO2010041138A3 Complex between human insulin and an amphiphilic polymer, and use of said complex for preparing a quick human insulin formulation
07/29/2010WO2010039641A3 Long term drug delivery devices with polyurethane-based polymers and their manufacture
07/29/2010WO2010033275A3 Orally administerable vaccine for yersinia pestis
07/29/2010WO2010025530A9 Proteic acid polymer, production processes, use of proteic acid polymer, pharmaceutical composition and method of treatment
07/29/2010WO2010014248A3 Antiviral activity of the protein scytovirin and methods of use
07/29/2010WO2010004535A3 Therapeutic methods and compositions employing peptide compounds
07/29/2010WO2009154988A3 Agr-mediated inhibition and dispersal of biofilms
07/29/2010WO2009149487A3 Compounds for treating symptoms associated with parkinson's disease
07/29/2010WO2009115658A9 Use of a caspase-1 inhibitor for treating atherosclerotic plaque
07/29/2010WO2009073808A3 Compositions and methods to modulate cell membrane resealing
07/29/2010WO2007089272A3 Non-toxic biofilm inhibitor
07/29/2010US20100192256 Novel Bacillus Thuringiensis Gene with Lepidopteran Activity
07/29/2010US20100192255 Novel Bacillus Thuringiensis Gene with Lepidopteran Activity
07/29/2010US20100191325 Coating containing pegylated hyaluronic acid and a pegylated non-hyaluronic acid polymer
07/29/2010US20100191040 Manipulation of ovarian primordial follicles
1 ... 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 ... 3163